APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+6.37%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.92B
AUM Growth
+$3.92B
(+6%)
Cap. Flow
+$265M
Cap. Flow
% of AUM
6.75%
Top 10 Holdings %
Top 10 Hldgs %
36.15%
Holding
133
New
20
Increased
42
Reduced
20
Closed
29
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$92.2M |
| 2 |
AstraZeneca
AZN
|
$84.8M |
| 3 |
Baxter International
BAX
|
$69.3M |
| 4 |
Stevanato
STVN
|
$64.3M |
| 5 |
Caribou Biosciences
CRBU
|
$59.1M |
Top Sells
| 1 |
Maravai LifeSciences
MRVI
|
$124M |
| 2 |
Medtronic
MDT
|
$66.4M |
| 3 |
Biogen
BIIB
|
$63.7M |
| 4 |
NeoGenomics
NEO
|
$61.7M |
| 5 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$55.7M |
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Technology | 1.13% |
| 3 | Financials | 0.61% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
IDEAYA Biosciences
IDYA
$2.3B
| $62.1M | 1.38% |
2,437,000
+367,000
| +18% | +$9.35M |
|
|
27
Caribou Biosciences
CRBU
$177M
| $59.1M | 1.31% |
+2,474,067
| New | +$59.1M |
|
|
CTLT
28
DELISTED
CATALENT, INC.
CTLT
| $53M | 1.17% |
398,000
-142,000
| -26% | -$18.9M |
|
|
GRTS
29
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $48.1M | 1.07% |
4,457,831
+2,335,767
| +110% | +$25.2M |
|
30
Legend Biotech
LEGN
$6.65B
| $45.2M | 1% |
894,000
+269,000
| +43% | +$13.6M |
|
|
OCDX
31
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $44.3M | 0.98% |
+2,398,000
| New | +$44.3M |
|
32
Pfizer
PFE
$141B
| $44.2M | 0.98% |
+1,026,800
| New | +$44.2M |
|
33
Arrowhead Research
ARWR
$3.72B
| $42.1M | 0.93% |
673,700
+569,700
| +548% | +$35.6M |
|
34
Shattuck Labs
STTK
$59.9M
| $41.3M | 0.91% |
2,025,000
+84,800
| +4% | +$1.73M |
|
35
Ultragenyx Pharmaceutical
RARE
$3.07B
| $41M | 0.91% |
+455,000
| New | +$41M |
|
36
Immunocore
IMCR
$1.73B
| $40.6M | 0.9% |
1,095,600
+494,600
| +82% | +$18.3M |
|
37
Avidity Biosciences
RNA
$5.99B
| $40.5M | 0.9% |
+1,645,000
| New | +$40.5M |
|
38
Iovance Biotherapeutics
IOVA
$807M
| $36.1M | 0.8% |
+1,462,200
| New | +$36.1M |
|
39
Insmed
INSM
$30.6B
| $35.6M | 0.79% |
1,292,000
+141,950
| +12% | +$3.91M |
|
40
Exact Sciences
EXAS
$9.23B
| $35.2M | 0.78% |
369,000
-221,000
| -37% | -$21.1M |
|
|
CMPS
41
Compass Pathways
CMPS
$449M
| $34.7M | 0.77% |
1,162,000
+162,000
| +16% | +$4.84M |
|
42
Alphatec Holdings
ATEC
$2.33B
| $34M | 0.75% |
2,786,000
+165,000
| +6% | +$2.01M |
|
43
Intellia Therapeutics
NTLA
$1.28B
| $33.7M | 0.75% |
251,000
-129,000
| -34% | -$17.3M |
|
|
IMAB
44
I-MAB
IMAB
$381M
| $32.9M | 0.73% |
454,000
-275,000
| -38% | -$19.9M |
|
|
SPNE
45
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $30.6M | 0.68% |
1,943,000
+418,002
| +27% | +$6.58M |
|
|
BLU
46
DELISTED
BELLUS Health Inc.
BLU
| $30.3M | 0.67% |
4,942,000
+692,000
| +16% | +$4.25M |
|
47
Kymera Therapeutics
KYMR
$3.02B
| $30.2M | 0.67% |
+514,500
| New | +$30.2M |
|
|
CYT
48
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $29.5M | 0.65% |
1,683,441
-124,953
| -7% | -$2.19M |
|
49
Altimmune
ALT
$326M
| $24.5M | 0.54% |
+2,167,900
| New | +$24.5M |
|
50
Vir Biotechnology
VIR
$749M
| $22.4M | 0.5% |
515,000
+353,000
| +218% | +$15.4M |
|